Copaxone—entirely synthetic with no animal-derived feedstock—is easier than Lovenox to reverse-engineer and manufacture within the lot-to-lot variation of the branded product. Given MNTA’s success in replicating Lovenox, there is little doubt, IMO, that MNTA has the ability to replicate Copaxone. You can bet your bottom dollar that, behind closed doors, Teva agrees.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”